SCPH director options canceled for cash and CVRs under $5.35 merger
Rhea-AI Filing Summary
scPharmaceuticals Inc. (SCPH) Form 4 filed for director Klaus R. Veitinger reports changes tied to a merger transaction completed on 10/07/2025. Pursuant to an Agreement and Plan of Merger with MannKind Corporation, a tender offer and related merger mechanics caused all outstanding company options with an exercise price below $5.35 to be cancelled and converted. Four option grants exercisable for a total of 72,174 underlying shares were cancelled: 30,000 @ $3.85, 19,750 @ $4.11, 16,300 @ $4.53, and 6,124 @ $3.37. Each cancelled option holder will receive cash equal to the excess of $5.35 over the option exercise price multiplied by the number of shares, plus one contingent value right (CVR) per share, subject to withholding.
Positive
- Defined cash consideration replaces uncertain option upside, providing immediate measurable value per cancelled option
- Contingent value rights (CVRs) awarded at one CVR per share preserve potential additional consideration
Negative
- Loss of long‑term upside from cancelled options that otherwise had expirations through 06/03/2035
- Cash payout depends on the fixed $5.35 merger price, capping upside above that level
Insights
Director's equity awards were converted into cash and CVRs under the merger terms.
The merger agreement with MannKind caused cancellation of options with exercise prices below $5.35, replacing potential equity upside with a fixed cash makeup and one CVR per share. This removes long‑term equity exposure for affected option holders and accelerates realization tied to the merger consideration.
Key dependencies include the merger effective mechanics and any CVR payment conditions; monitor CVR terms and any escrow/withholding timelines in the near term.
Cancellation affects 72,174 option shares across four grants, creating immediate defined value.
The cash calculation equals ( $5.35 minus the option exercise price ) times shares for each cancelled grant; this crystallizes value today instead of retaining optionality. Reported cancelled grants include expirations ranging from 06/18/2029 to 06/03/2035.
Watch for timing of cash payments and CVR distributions; those will determine ultimate realized value for option holders over the coming months.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) | 30,000 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 19,750 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 16,300 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 6,124 | $0.00 | -- |
Footnotes (1)
- In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, (Continued from footnote 1) without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.
